227
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Impacts of the COVID-19 public health restrictions on substance use, mental health, and psychosocial functioning among individuals with alcohol use disorder

, , , , , , , , , , ORCID Icon & show all
Pages 712-723 | Received 19 Dec 2021, Accepted 04 Oct 2022, Published online: 23 Nov 2022
 

ABSTRACT

Background: The COVID-19 pandemic has been associated with major psychosocial disruptions and there is particular concern for individuals with substance use disorders.

Objectives: This study characterized the psychosocial and experiential impacts of the pandemic on individuals seeking alcohol use disorder (AUD) recovery, including pandemic impacts on self-reported drinking, heavy drinking, tobacco, cannabis, and stimulant use.

Methods: Participants were 125 AUD+ individuals (% males: 57.60; Mage = 49.11, SD = 12.13) reporting on substance use from January 1st–24th March, 2020 (pre-pandemic) and since the stay-at-home orders commenced, 24th March–June 28th 2020 (intra-pandemic). Within-subjects changes were examined and a latent profile analysis was performed to identify subgroups differentially impacted by the pandemic.

Results: Large proportions reported psychosocial impacts of COVID-19, but drinking and other substance use did not reveal significant changes. Latent profile analyses revealed two subgroups: Profile 1 (n = 41/125), “Moderately Impacted”) and Profile 2 (n = 84/125), “Severely Impacted”). Compared to the pre-pandemic period, the group that was moderately impacted by the pandemic exhibited significantly fewer heavy drinking days (p = .02) during the intra-pandemic period, but no other substance use changes. The group showing severe pandemic impacts did not exhibit changes in alcohol or other drug use but evidenced more severe anxiety and depression (ps < .001).

Conclusions: We found heterogeneous subtypes of pandemic-related impacts in AUD recovery patients. There is need to provide psychosocial support to this particular population and further monitoring substance use and mental health.

Disclosure statement

JM is a principal and senior scientist at BEAM Diagnostics, Inc and a consultant to Clairvoyant Therapeutics, Inc. No other authors have interests to declare.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/00952990.2022.2134021.

Additional information

Funding

This research was supported by a National Institute of Health [grant ref: R01 AA025849; PIs: James MacKillop & J.F. Kelly]. This institution had no role in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.